--- title: "Pre-market Trend | Amgen (AMGN.US)" type: "News" locale: "en" url: "https://longbridge.com/en/news/286964426.md" description: "Amgen has maintained stable performance in the biotechnology sector, with its stock price recently rising slightly by 1.96% amid market turbulence. With the changing global health demands, particularly in the context of increased attention to chronic and rare diseases, Amgen's business has sustainable growth potential. Recently, Amgen has made significant progress in research and development investments and strategic partnerships. In the biotechnology field, continuous innovation and the expansion of its product portfolio have enabled the company to occupy a favorable position in the competition. Meanwhile, the rise in stock price also reflects the market's recognition of its future growth potential. Technically, the emergence of bullish signals in MACD, combined with recent stock price performance and trading volume, seems to indicate an improvement in market expectations for Amgen. Therefore, investors should closely monitor changes in chemotherapy innovations and the timing of new drug launches to capture potential rebound opportunities in stock prices. In the short term, Amgen's performance will be driven by key factors such as R&D progress and the approval status of new therapies. This article provides only technical analysis and market information for reference and does not constitute any investment advice. The market carries risks, and investments should be made with caution" datetime: "2026-05-20T13:00:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286964426.md) - [en](https://longbridge.com/en/news/286964426.md) - [zh-HK](https://longbridge.com/zh-HK/news/286964426.md) --- # Pre-market Trend | Amgen (AMGN.US) Amgen has maintained stable performance in the biotechnology sector, with its stock price recently rising slightly by 1.96% amid market turbulence. With the changing global health demands, particularly in the context of increased attention to chronic and rare diseases, Amgen's business has sustainable growth potential. Recently, Amgen has made significant progress in research and development investment and strategic partnerships. In the biotechnology field, continuous innovation and the expansion of its product portfolio have enabled the company to occupy a favorable position in the competition. Meanwhile, the rise in stock price also reflects the market's recognition of its future growth potential. On the technical side, the emergence of bullish signals in the MACD, combined with recent stock price performance and trading volume, seems to indicate an improvement in market expectations for Amgen. Therefore, investors should closely monitor changes in chemotherapy innovations and the timing of new drug launches to capture potential rebound opportunities in the stock price. In the short term, Amgen's trend will be driven by key factors such as R&D progress and the approval status of new therapies. _This article provides technical analysis and market information for reference only and does not constitute any investment advice. The market carries risks, and investments should be made cautiously._ ### Related Stocks - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) ## Related News & Research - [Amgen Announces CFO Transition and Leadership Succession Plan](https://longbridge.com/en/news/286964358.md) - [AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH | AMGN Stock News](https://longbridge.com/en/news/286959850.md) - [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md) - [](https://longbridge.com/en/news/286807703.md) - [REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval](https://longbridge.com/en/news/286443456.md)